For decades, RAS mutations were considered undruggable — a death sentence for targeted therapy in lung cancer. The emergence of agents capable of broadly inhibiting RAS signaling represents one of the most significant shifts in thoracic oncology, and data from this NEJM trial add important clinical weight to that evolving story.
This trial evaluated daraxonrasib, a pan-RAS inhibitor, in patients with previously treated RAS-mutant non–small-cell lung cancer (NSCLC). Unlike earlier agents such as sotorasib and adagrasib, which target only the KRAS G12C variant, daraxonrasib is designed to inhibit multiple RAS isoforms and mutation subtypes. The study, published in the New England Journal of Medicine, examined response rates, progression-free survival, and safety in a cohort of patients who had progressed on prior systemic therapy. Specific efficacy metrics and full breakdown by mutation subtype are detailed in the original publication, making it worth consulting directly for precise figures.
Contextually, this finding matters because KRAS G12C accounts for only roughly 13% of NSCLC cases, while a broader swath of RAS-mutant tumors — including KRAS G12D, G12V, NRAS, and HRAS variants — have until recently lacked any approved targeted option. A pan-RAS approach theoretically broadens the treatable population considerably. The key scientific challenge has always been achieving RAS inhibition without unacceptable on-target toxicity to normal cells, which also rely on RAS signaling. Whether daraxonrasib navigates that therapeutic window safely and durably — particularly in later lines — will determine its clinical footprint. As a phase I/II signal-finding study in a pretreated population, it establishes proof of concept but cannot yet confirm overall survival benefit or optimal sequencing. Replication in larger randomized trials will be essential. Still, the paradigm shift from KRAS G12C-only targeting toward broader RAS inhibition marks a genuinely meaningful inflection point for this patient population.